Antimetabolites, Antineoplastic
"Antimetabolites, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antimetabolites that are useful in cancer chemotherapy.
| Descriptor ID |
D000964
|
| MeSH Number(s) |
D27.505.519.186.144 D27.505.954.248.144 D27.888.569.042.030
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antimetabolites, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antimetabolites, Antineoplastic".
This graph shows the total number of publications written about "Antimetabolites, Antineoplastic" by people in this website by year, and whether "Antimetabolites, Antineoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 8 | 6 | 14 |
| 1996 | 11 | 6 | 17 |
| 1997 | 10 | 5 | 15 |
| 1998 | 14 | 7 | 21 |
| 1999 | 11 | 9 | 20 |
| 2000 | 9 | 5 | 14 |
| 2001 | 21 | 9 | 30 |
| 2002 | 14 | 12 | 26 |
| 2003 | 10 | 12 | 22 |
| 2004 | 14 | 10 | 24 |
| 2005 | 17 | 15 | 32 |
| 2006 | 17 | 17 | 34 |
| 2007 | 16 | 11 | 27 |
| 2008 | 11 | 10 | 21 |
| 2009 | 13 | 12 | 25 |
| 2010 | 17 | 9 | 26 |
| 2011 | 10 | 9 | 19 |
| 2012 | 11 | 9 | 20 |
| 2013 | 20 | 12 | 32 |
| 2014 | 15 | 10 | 25 |
| 2015 | 14 | 3 | 17 |
| 2016 | 8 | 3 | 11 |
| 2017 | 7 | 6 | 13 |
| 2018 | 12 | 4 | 16 |
| 2019 | 8 | 3 | 11 |
| 2020 | 3 | 5 | 8 |
| 2021 | 3 | 5 | 8 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 6 | 6 |
| 2024 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antimetabolites, Antineoplastic" by people in Profiles.
-
Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
-
Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024 Oct; 71(10):e31213.
-
Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
-
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2024 May; 24(5):e196-e204.
-
Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Oncogene. 2024 03; 43(11):776-788.
-
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):260-268.e2.
-
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024 02; 99(2):E32-E36.
-
Significant erythroid megaloblastic changes in patients treated with allopurinol during maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 11; 70(11):e30631.
-
Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Clin Transl Sci. 2023 11; 16(11):2130-2143.
-
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Cancer Biol Med. 2023 06 27; 20(8).